Human/Mouse ERK2/MAPK2 (K52R) (GenBank Accession No. NM_0011949), full length with mutation on lysine52 to arginine and with an N-terminal His-tag, MW=42 kDa, expressed in E. coli . The K52R mutation prevents ATP binding, making the kinase inactive.

ERK2, MAPK1, mitogen-activated protein kinase 1, Extracellular Signal-Regulated Kinase 2, PRKM

inactive

45 mM Tris-HCl, pH 8.0, 124 mM NaCl, 2.4 mM KCl, 125 mM imidazole, 3 mM DTT, 10% glycerol.

Aqueous buffer solution

>6 months at -80°C.

Useful as a substrate for MEK1.

1. Robinson, M.J., et al. Biochemistry. 1996 May 7;35(18):5641-6.
2. Mitsushima, M. et al. Cell Res. 313 (9), 1830- 1838 (2007).
3. Wille, L. et al. Mol. Immunol. 44 (12), 3085- 3091 (2007).

Application Reference(s):
1. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity (2017)

The human and mouse versions of this protein share 100% amino acid homology.

Avoid freeze/thaw cycles

Kinase/Substrate

Recombinant Protein